News - Page 51 - Psychedelic Alpha

Our 🎯 Q1 2026 Psychedelic Pipeline Bullseye Charts are now available.

Read more about the article State of Kentucky Sets aside $42 Million for Psychedelic Research, with Focus on Ibogaine

State of Kentucky Sets aside $42 Million for Psychedelic Research, with Focus on Ibogaine

Post published:May 31, 2023
Post category:News

Read more about the article Algernon Pharmaceuticals Receives Notice of Allowance from the Japanese Patent Office for Repirinast and the Treatment of CKD

Algernon Pharmaceuticals Receives Notice of Allowance from the Japanese Patent Office for Repirinast and the Treatment of CKD

Post published:May 31, 2023
Post category:Press Release

Read more about the article COMPASS Pathways’ Co-Founder Ekaterina Malievskaia to Step Down as Chief Innovation Officer

COMPASS Pathways’ Co-Founder Ekaterina Malievskaia to Step Down as Chief Innovation Officer

Post published:May 31, 2023
Post category:Press Release

Read more about the article Psychedelic Bulletin #138: Delix’s Non-Hallucinogenic Psychedelic Enters the Clinic; Arizona Earmarks $5m for Whole Mushroom Psilocybin Trials; MEPs form EU Action Group

Psychedelic Bulletin #138: Delix’s Non-Hallucinogenic Psychedelic Enters the Clinic; Arizona Earmarks $5m for Whole Mushroom Psilocybin Trials; MEPs form EU Action Group

Post published:May 30, 2023
Post category:Psychedelic Bulletin

Read more about the article Silo Pharma Commences Study of Novel Joint Homing Peptide SPU-21

Silo Pharma Commences Study of Novel Joint Homing Peptide SPU-21

Post published:May 30, 2023
Post category:Press Release

Read more about the article Numinus to research COMP360 psilocybin therapy in treatment-resistant depression as part of large phase 3 study

Numinus to research COMP360 psilocybin therapy in treatment-resistant depression as part of large phase 3 study

Post published:May 30, 2023
Post category:Press Release

Read more about the article FILAMENT HEALTH ANNOUNCES INTERIM RESULTS FROM PHASE I CLINICAL TRIAL AT THE UNIVERSITY OF CALIFORNIA SAN FRANCISCO

FILAMENT HEALTH ANNOUNCES INTERIM RESULTS FROM PHASE I CLINICAL TRIAL AT THE UNIVERSITY OF CALIFORNIA SAN FRANCISCO

Post published:May 30, 2023
Post category:Press Release

Read more about the article COMPASS Pathways to participate in upcoming Jefferies Healthcare Conference

COMPASS Pathways to participate in upcoming Jefferies Healthcare Conference

Post published:May 27, 2023
Post category:Press Release

Read more about the article Terran Biosciences announces new breakthroughs in the chemistry of MDMA and its enantiomers and analogs, discovers new salts and polymorphs, publishes PCT application.

Terran Biosciences announces new breakthroughs in the chemistry of MDMA and its enantiomers and analogs, discovers new salts and polymorphs, publishes PCT application.

Post published:May 26, 2023
Post category:Press Release

Read more about the article Sunstone Therapies presents data at ASCO showing positive long-term follow-up results from psilocybin therapy in cancer patients with major depressive disorder (MDD)

Sunstone Therapies presents data at ASCO showing positive long-term follow-up results from psilocybin therapy in cancer patients with major depressive disorder (MDD)

Post published:May 26, 2023
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond. Psy Alpha Ltd is a company registered in England and Wales (16989109).

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.